| 发明名称 | Use of TNFα inhibitor for treatment of psoriasis | ||
| 摘要 | The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. | ||
| 申请公布号 | US8986693(B1) | 申请公布日期 | 2015.03.24 |
| 申请号 | US201414510821 | 申请日期 | 2014.10.09 |
| 申请人 | AbbVie Biotechnology Ltd. | 发明人 | Hoffman Rebecca S.;Weinberg Mark;Taylor Lori K.;Chartash Elliot K.;Yan Philip;Granneman George R. |
| 分类号 | C07K16/24;A61K39/395 | 主分类号 | C07K16/24 |
| 代理机构 | Foley Hoag LLP | 代理人 | Foley Hoag LLP |
| 主权项 | 1. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 90 response at week 12 of the treatment. | ||
| 地址 | Hamilton BM | ||